Autologous Blood Stem Cell Transplantation in Hematological Malignancies

References

• Gale R.P., Butturini A., Henon P. Is there a reason to use blood cell transplants?. Int. J. Cell Cloning 1992; 10(Suppl. l)74–78
   Google Scholar
• Richman C.M., Weiner R.S., Yankee R.A. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031–1039
   PubMed Web of Science ®Google Scholar
• Siena S., Bregni M., Brando B., et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74(6)1905–1914
   PubMed Web of Science ®Google Scholar
• Duhrsen U., Villeval J.L., Boyd J., et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72(6)2074–2081
   PubMed Web of Science ®Google Scholar
• Lieschke G.J., Burgess A.W. Drug therapy: Granulocyte colony stimulating factor and Granulocyte-Mac-rophage colony stimulating factor. N. Engl. J. Med. 1992; 327(1)28–35
   PubMed Web of Science ®Google Scholar
• Socinski M.A., Cannistra S.A., Elias A., et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; i: 1194–1198
   Google Scholar
• Brugger W., Bross K., Frisch J., et al. Mobilization of peripheral blood progenitor cells by sequential administra tion of of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etopo-side, ifosfamide and cisplatin. Blood 1992; 79(5)1193–1200
   PubMed Web of Science ®Google Scholar
• Teshima T., Harada M., Takamatsu Y., et al. Cy-totoxic drug and cytotoxic drug/G-CSF mobilization of pe ripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1992; 10: 215–220
   PubMed Web of Science ®Google Scholar
• Fermand J.P., et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple my eloma. Nouv. Rev. Fr. Hematol. 1991; 33(6)525–528
   PubMedGoogle Scholar
• To L.B., Roberts M.M., Haylock D.N., et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Trans plant 1992; 9: 277–284
   PubMed Web of Science ®Google Scholar
• To L.B., Juttner C.A. Peripheral blood stem cell autografting: a new therapeutic option for AML?. Br. J. Haematol. 1987; 66: 285–288
   PubMed Web of Science ®Google Scholar
• Chao N.J., Schriber J.R., Grimes K., et al. Gran ulocyte Colony-Stimulating Factor “mobilized” Peripheral Blood Progenitor Cells Accelerate Granulocyte and Platelet Recovery after High-Dose Chemotherapy. Blood 1993; 81(8)2031–2035
   PubMed Web of Science ®Google Scholar
• Liu K.Y., Akashi K., Harada M., et al. Kinetics of circulating haematopoietic progenitors during chemother apy-induced mobilization with or without granulocyte colony-stimulating factor. Br. J. Haematol. 1993; 84: 31–38
   PubMed Web of Science ®Google Scholar
• Jones H.M., Jones S.A., Khwaja A., et al (1993) Critical analysis of the parameters used for monitoring peripheral blood stem cell (PBSC) harvesting. Annual Scientific Meeting of the Br. Soc. Haematol., Bournemouth, 1993, Abstract 46
   Google Scholar
• Lowry P.A., Tabbara I.A. Peripheral Hema-topoietic stem cell transplantation: current concepts. Exp. He-matol. 1992; 20: 937–942
   PubMed Web of Science ®Google Scholar
• Siena S., Bregni M., Brando B., et al. Flow cyto-metry for clinical estimation of circulating hematopoietic pro genitors for autologous transplantation in cancer patients. Blood 1991; 77(2)400–409
   PubMed Web of Science ®Google Scholar
• Hohaus S., Goldschmodt Ehrhardt R., Haas W. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp. Hematol. 1993; 21: 508–514
   PubMed Web of Science ®Google Scholar
• Serke S., Sauerlich S., Huhn D. Multiparameter flow-cytometrical quantitation of circulating CD34+ cells: correlation to the quantitation of circulating haemopoietic pro genitor cells by in vitro colony assay. Br. J. Haematol. 1991; 77(4)453–459
   PubMedGoogle Scholar
• Kanz L., Brugger W., Bross K.J., Mertelsmann R. CorreIation analyses between CD34+ cells and clon-ogenic progenitors mobilized into the peripheral blood by IL-3 + GM-CSF following polychemotherapy in cancer patients. Int. J. Cell Cloning 1992; 10(Suppl. 1)68–70
   Google Scholar
• Serke S., Abe Y., Kirsch A., Huhn D. Pheno-typing of peripheral blood hemopoietic progenitor cells-in vi tro cultures using CD34-/CD33-immunomagnetic purging. Eur. J. Haematol. 1991; 47: 361–366
   PubMed Web of Science ®Google Scholar
• Civin C.I. Purified progenitor/stem cells: back ground, feasibility, and prospects for clinical transplantation. Int. J. Cell Cloning 1992; 10(Suppl. 1)16–19
   Google Scholar
• Sovalat H., Liang H., Wunder E., Henon Ph. Flow cytometry characterization of CD34+ cells in bone mar row, cytapheresis products, and cord blood at birth. Int. J. Cell Cloning 1992; 10(Suppl. 1)20–22
   Google Scholar
• Bender J.G., Williams S.F., Myers S., et al. Char acterization of chemotherapy mobilized peripheral blood pro genitor cells for use in autologous stem cell transplantation. Bone Marrow Transplant 1992; 10: 281–285
   PubMed Web of Science ®Google Scholar
• Kessinger A., Armitage J.O. The Evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77(2)211–213
   PubMed Web of Science ®Google Scholar
• Gianni A.M., Siena S., Bregni M., et al. Granu-locyte-macrophage colony-stimulating factor to harvest cir culating haemopoietic cells for autotransplantation. Lancet 1989; ii: 580–584
   Google Scholar
• Elias A.D., Ayash L., Anderson K.C., et al. Mo bilization of peripheral blood progenitor cells by chemother apy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79(11)3036–3044
   PubMed Web of Science ®Google Scholar
• Kessinger A., Vose J.M., Bierman P.J., Armitage J.O. High-dose cyclophosphamide, etoposide and car-mustine and peripheral stem cell transplantation for patients with relapsed Hodgkin's disease and bone marrow abnormal ities. Int. J. Cell Cloning 1992; 10(Suppl. 1)135–137
   PubMedGoogle Scholar
• Henon P.R., Liang H., Beck-Wirth G., et al. Com parison of hematopoietic and immune recovery after autolo gous bone marrow and blood stem cell transplants. Bone Mar row Transplant 1992; 9: 285–291
   PubMed Web of Science ®Google Scholar
• Molineux G., Pojda Z., Hampson I.N., et al. Transplantation potential of peripheral blood stem cells induced by granulocyte colony stimulating factor. Blood 1990; 76: 2153–2158
   PubMed Web of Science ®Google Scholar
• Demuynck H., Pettengell R., de Campos E., et al. The capacity of peripheral blood stem cells mobilized with chemotherapy plus G-CSF to repopulate irradiated marrow stroma in vitro is similar to that of bone marrow. Eur. J. Cancer 1992; 28(2/3)381–386
   PubMedGoogle Scholar
• Brito-Babapulle F., Bowcock S.J., Marcus R.E., et al. Autografting for patients with chronic myeloid leu kemia in chronic phase: peripheral blood stem cell may have a finite capacity for maintaining haemopoiesis. Br. J. Hae matol. 1989; 73: 76–81
   PubMed Web of Science ®Google Scholar
• Pagliuca A., Dobbs J., Mufti G.J. Autologous reconstitution using the BEAM regimen and G-CSF in resis tant lymphoid disease. Blood 1992; 80(Suppl. 1)418A
   Google Scholar
• Brenner M.K., Rill D.R., Moen R.C., et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Gorin N.C., Aegerter P., Auvert B., et al. Autolo gous bone marrow transplantation for acute myelocytic leu kemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75(8)1606–1614
   PubMed Web of Science ®Google Scholar
• To L.B., Russel J., Moore S., Juttner C.A. Residual leukemia cannot be detected in very early remission peripheral blood stem cell collections in acute non-lympho-blastic leukemia. Leuk. Res. 1987; 11: 327–329
   PubMed Web of Science ®Google Scholar
• Goto T., Nishikori M., Arlin Z., et al. Growth char acteristics of leukemic and normal hematopoietic cells in Phil adelphia-positive chronic myelogenous leukemia and effects of intensive treatment. Blood 1982; 59: 793–808
   PubMed Web of Science ®Google Scholar
• Korbling M., Burke P., Braine H., et al. Successful engraftment of blood-derived normal hematopoietic stem cells in chronic myelogenous leukemia. Exp. Hematol. 1981; 9: 684–690
   PubMed Web of Science ®Google Scholar
• Sessarego M., Fugazza G., Frassoni F., et al. Cy-togenetic analysis of hemopoietic peripheral blood cells col lected by leukapheresis after intensive chemotherapy in ad vanced-phase Philadelphia-positive chronic myelogenous leukemia. Leukemia 1992; 6(7)715–719
   PubMed Web of Science ®Google Scholar
• Castaigne S., Delcortivo L., Leverger G., et al. Au-togreffes a partir des cellules souches sanguines. Nouv. Rev. Fr. Hematol. 1988; 30(1–2)69–73
   PubMedGoogle Scholar
• Langlands K., Anderson J.S., Parker A.C., Anthony R.S. Polymerase chain reaction analysis of tumor con tamination in peripheral blood stem cell harvests. Int. J. Cell Cloning 1992; 10(Suppl. 1)95–97
   Google Scholar
• Hardingham J.E., Kotasek D., Sage R.E., et al. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplan tation. Bone Marrow Transplant 1993; 11: 15–20
   PubMed Web of Science ®Google Scholar
• Gordon M.Y., Dowding C.R., Riley G.P., et al. Altered adhesive interactions with marrow stroma of hema topoietic progenitor cells in chronic myeloid leukemia. Na ture 1987; 328: 342–344
   PubMed Web of Science ®Google Scholar
• Bergsagel D. Plasma cell neoplasms-general consid erations. Hemarology4th edn., W.J. Williams, E. Beu-Tler, A.J. Erslev, M.A. Lichtmann. McGraw-Hill, New York 1990; 1101–1109
   Google Scholar
• Marit G., Pico J.L., Boiron J.M., et al. Autologous blood stem cell transplantation in high risk myeloma (abstr). Exp. Hematol. 1991; 19: 558
   Web of Science ®Google Scholar
• Barlogie B., Gahrton G. Bone marrow trans plantation in multiple myeloma. Bone Marrow Transplant 1991; 7: 71–79
   PubMed Web of Science ®Google Scholar
• Bell A.J., Figes A., Oscier D.G., Hamblin T.J. Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: initial experience in three patients. Br. J. Haematol. 1987; 66: 63–68
   PubMed Web of Science ®Google Scholar
• Kessinger A., Armitage J.O. Peripheral stem cell transplantation for patients with non-Hodgkin lymphoma. Int. J. Cell Cloning 1992; 10(Suppl. 1)127–128
   Google Scholar
• Kotasek D., Sage R.E., Juttner C.A., To L.B. Autologous transplantation in non-Hodgkin's lymphomas us ing high-dose cyclophosphamide mobilized blood stem cells. The Adelaide experience. Int. J. Cell Cloning 1992; 10(Suppl. 1)129–131
   Google Scholar
• Reiffers J., Korbling M., Labopin M., et al. Au tologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. Int. J. Cell Cloning 1992; 10(Suppl. 1)111–113
   Google Scholar
• Korbling M., Fliedner T.M., Holle R., et al. Au tologous blood stem cell (ABSCT) versus purged bone mar row transplantation (pABMT) in standard risk AML: influ ence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991; 7: 343–349
   PubMed Web of Science ®Google Scholar
• Reiffers J., Trouette R., Marit G., et al. Autologous blood stem cell transplantation for chronic granulocytic leu kemia in transformation: a report of 47 cases. Br. J. Hae-matol. 1991; 77: 339–345
   PubMed Web of Science ®Google Scholar
• The University of Texas M. D. Anderson Cancer Center. Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery af ter preparative therapy. Human Gene Therapy 1993; 4: 71–85
   PubMed Web of Science ®Google Scholar
• Bregni M., Magni M., Siena S., et al. Human pe ripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood 1992; 80: 1418–1422
   PubMed Web of Science ®Google Scholar
• Dreger P., Suttorp M., Haferlach T., et al. Allo-geneic granulocyte colony stimulating factor-mobilized pe ripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404–1407
   PubMed Web of Science ®Google Scholar
• Matsunaga T., Sakamaki S., Kohgo Y., et al. Re-combinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Mar row Transplant 1993; 11: 103–108
   PubMed Web of Science ®Google Scholar
• Ho A.D., Haas R., Korbling M., et al. Utilization of recombinant human GM-CSF to enhance peripheral pro genitor cell yield for autologous transplantation. Bone Mar row Transplant 1991; 7(Suppl. 1)13–17
   PubMedGoogle Scholar